The information that must be included and the format in which it needs to be presented are outlined. The process of review by the FDA is described, and the outcomes and sponsor's responses are discussed. The actions necessary to maintain an open IND are set out.
Finally, the regulatory provisions for expanded-access use of investigational drugs are described.
Specify the role of an IND and the contexts in which it is required
Access key regulatory documents relating to INDs
Describe the contents and format of an IND submission
Describe the process of FDA review of an IND, the possible outcomes and sponsor's responses
Identify actions necessary to maintain an active IND
Specify options for expanded-access use of investigational drugs
An outline of the module's scope and objectives, and notes on terminology.
Introduction to Investigational New Drug Applications (INDs)
This session explains the role and legal status of an IND, sets out the contexts in which one must be filed, summarises the responsibilities of sponsors and investigators, and outlines the pre-submission process.
IND content and format requirements
This session sets out IND contents required by regulations and describes how these are incorporated in a CTD-formatted submission. The significance of the FDA forms 1571 and 1572 are discussed. The major components of an application are outlined: general investigational plan, investigator's brochure, clinical protocol, Quality/CMC information, nonclinical data, and clinical information.
Filing and FDA review
Options and requirements for submission of an IND are set out, and the review procedure and its outcomes are described. The roles of FDA reviewers are outlined. The significance of a clinical hold and the sponsor's response to a hold are discussed.
Maintenance of an IND
This session identifies the various types of IND amendments and reports: protocol amendments, IND safety reports, annual reports, and information amendments. It explains when they need to be made and outlines the regulations that govern them. The responsibilities of sponsors and investigators to report safety findings are described, as are requirements for financial disclosure and record retention.
This session describes the various types of expanded-access use of investigational drugs to treat patients outside of clinical trials and sketches a scenario of emergency use.
Multiple-choice mastery assessment.